| Trial Reference/Name |
Tumor Stream/s |
Age |
Location |
Short Title |
Eligibility Criteria |
Trial Open |
ACTRN12613000423718
 |
Rhabdomyosarcoma, Soft tissue sarcomas, Osteogenic sarcoma, Ewing sarcoma |
0-21 |
NSW,WA |
A phase I study of vinorelbine, cyclophosphamide and Rapamycin for recurrent malignancies in children |
Click Here |
2011 |
ACTRN12613000987763
|
Sarcoma |
18-60 |
VIC |
A pilot surveillance study investigating whole body magnetic resonance imaging and other diagnostic procedures in people at high risk of cancer |
Click Here |
2013 |
ACTRN12615000527561
|
All Sarcoma |
15-25 |
SA,TAS |
A pilot randomised controlled trial of a structured exercise intervention after the completion of cancer treatment in adolescents and young adults |
Click Here |
2015 |
ASSG02-09: RFK ISKS
|
All Sarcoma |
No age limitations |
NSW,QLD,SA,VIC,WA |
International Sarcoma Kindred Study: Identification of inherited risk in individuals with sarcoma |
Click Here |
2009 |
NCT01479283
|
All Sarcoma |
12+ |
SA |
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center International Randomized Controlled Trial Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections With Endoprosthetic Replacements |
Click Here |
2013 |
NCT02365441
|
Gastrointestinal Stromal Tumour (GIST) |
18+ |
ACT,NSW,QLD,SA,TAS,VIC,WA |
A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour |
Click Here |
2015 |
NCT02379845
|
Soft Tissue Sarcoma |
18 + |
NSW |
NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall |
Click Here |
February 2015 |
NCT02484443
|
Recurrent osteosarcoma |
< 29 yrs |
NSW,QLD,SA,VIC |
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma |
Click Here |
2015 |
NCT02601937
|
Synovial sarcoma, epithelioid sarcoma, extraskeletal myxoid chondrosarcoma, epithelioid MPNST |
6 months to 21 yrs |
NSW,QLD,VIC,WA |
A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma |
Click Here |
2016 |
Search for a Clinical Study
Last update: 22-Feb-2016 12:47 PM
